Effect of statins and calcium channel blockers on all-cause mortality and cardiovascular and cerebrovascular disease mortality in 958 Chinese hospitalized patients with peripheral arterial disease after 13 months of follow-up

Journal of Health Science

Volumn 53, Issue 2, 2007, Pages 226-233

  Li, Xiankai ^a   Li, Jue ^a   Nguyen, Thach ^b   Zhao, Mingzhong ^a   Zheng, Liqiang ^a   Hasimu, Buaijiaer ^a   Yu, Jinming ^a   Luo, Yingyi ^a   Hu, Dayi ^a  

^a TONGJI UNIVERSITY   (China)

^b St Mary Medical Center   (United States)

Author keywords

Ankle brachial index; Calcium channel blockers; Mortality; Peripheral arterial disease; Statins

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTERY DISEASE; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FOLLOW UP; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR;

EID: 34047123149     PISSN: 13449702     EISSN: 13475207     Source Type: Journal    
DOI: 10.1248/jhs.53.226     Document Type: Article

References (35)

1. Criqui, M. H., Denenberg, J. O., Langer, R. D. and Fronek, A. (1997) The epidemiology of peripheral arterial disease: importance of identifying the population at risk. Vasc. Med., 2, 221-226.
2. Selvin, E. and Erlinger, T. P. (2004) Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation, 110, 738-743.
3. Dormandy, J. A., Heeck, L. and Vig, S. (1999) The fate of patients with critical leg ischemia. Semin. Vasc. Surg., 12, 142-147.
4. Dieter, R. S., Chu, W. W., Pacanowski, J. P., McBride, P. E. and Tanke, T. E. (2001) The significance of lower extremity peripheral arterial disease. Clin. Cardiol., 25, 3-10.
5. Criqui, M. H., Langer, R. D., Fronek, A., Feigelson, H. S., Klauber, M. R., McCann, T. J. and Browner, D. (1992) Mortality over a period of 10 years in patients with peripheral arterial disease. N. Engl. J. Med., 326, 381-386.
6. Schroll, M. andMunck, O. (1981) Estimation of peripheral atherosclerotic disease by ankle blood pressure measurements in a population study of 60 year old men and women. J. Chronic. Dis., 34, 261-269.
7. Newman, A. B., Sutton-Tyrrell, K. and Kuller, L. H. (1993) Lower-extremity arterial disease in older hypertensive adults. Arterioscler. Thromb., 13, 555-562.
8. Newman, A. B., Sutton-Tyrrell, K., Vogt, M. T. and Kuller, L. H. (1993) Morbidity and mortality in hypertensive adults with a low ankle/arm blood pressure. JAMA, 270, 487-489.
9. Fowkes, F. G., Housley, E., Cawood, E. H., Macintyre, C. C., Ruckley, C. V. and Prescott, R. J. (1991) Edinburgh Artery Study. Prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int. J. Epidemiol., 20, 384-392.
10. Rockson, S. G. and Cooke, J. P. (1998) Peripheral arterial insufficiency: Mechanism, natural history, and therapeutic opinions. Adv. Intern.Med., 43, 253-277.
11. Newman, A. B., Shemanski, L., Manolio, T. A., Cushman, M., Mittelmark, M., Polak, J. F., Power, N. R. and Siscovick, D. (1999) Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. Arterioscler. Thromb. Vasc. Biol., 19, 538-545.
12. Vogt, M. T., Cauley, J. A., Newman, A. B., Kuller, L. H. and Hulley, S. B. (1993) Deceased ankle/arm blood pressure index and mortality in elderly women. JAMA, 270, 465-469.
13. Vogt, M. T., McKenna, M., Anderson, S. J., Wolfson, S. K. and Kuller, L. H. (1993) The relationship between ankle-arm index and mortality in older men and women. J. Am. Geriatr. Soc., 41, 523-530.
14. Leng, G. C., Fowkes, F. G., Lee, A. J., Dunbar, J., Housley, E. and Ruckley, C. V. (1996) Use of the ankle brachial pressure index to predict cardiovascular events and death. BMJ, 313, 1440-1444.
15. Kuller, L. H., Shemanski, L., Psaty, B. M., Borhani, N. O., Gardin, J., Haan, M. N., O'Leary, D. H., Savage, P. J., Tell, G. S. and Tracy, R. (1995) Subclinical disease as an independent risk factor for cardiovascular disease. Circulation, 92, 720-726.
16. McKenna, M., Wolfson, S. and Kuller, L. (1991) The ratio of ankle and arm arterial pressure as an independent predictor of mortality. Atherosclerosis, 87, 119-128.
17. Resnick, H. E., Lindsay, R. S., McDermott, M. M., Devereux, R. B., Jones, K. L., Fabsitz, R. R. and Howard, B. V. (2004) Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: the Strong Heart Study. Circulation, 109, 733-739.
18. Hirsch, A. T., Haskal, Z. J., Hertzer, N. R., Bakal, C. W., Creager, M. A., Halperin, J. L., Hiratzka,, L. F., Murphy, W. R., Olin, J. W., Puschett, J. B., Rosen-field, K. A., Sacks, D., Stanley, J. C., Taylor, L. M., Jr., White, C. J., White, J., White, R. A., Antman, E. M., Smith, S. C., Jr., Adams, C. D., Anderson, J. L., Faxon, D. P., Fuster, V., Gibbons, R. J., Hunt, S. A., Jacobs, A. K., Nishimura, R., Ornato, J. P., Page, R. L., Riegel, B.; American Association for Vascular Surgery; Society for Vascular Surgery; Society for Cardiovascular Angiography and Interventions; Society for Vascular Medicine and Biology; Society of Interventional Radiology; ACC/AHA Task Force on Practice Guidelines Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease; American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; Vascular Disease Foundation. (2006) ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients with Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; Trans Atlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation, 113, e463-e654.
19. Heart Protection Study Collaborative Group (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet, 360, 7-22.
20. Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., Kamper, A. M., Macfarlane, P. W., Meinders, A. E., Norrie, J., Packard, C. J., Perry, I. J., Stott, D. J., Sweeney, B. J., Twomey, C. Westendorp, R. G.; PROSPER stydy group., and PROspective Study of Pravastatin in the Elderly at Risk. (2002) Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet, 360, 1623-1630.
21. Pedersen, T. R., Olsson, A. G., Faergeman, O., Kjekshus, J., Wedel, H., Berg, K., Wilhelmsen, L., Haghfelt, T., Thorgeirsson, G., Pyorala, K., Miettinen, T., Christophersen, B., Tobert, J. A., Musliner, T. A. and Cook, T. J. (1998) Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation, 97, 1453-1460.
22. Cannon, C. P. and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med., 350, 1495-1504.
23. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA, 288, 2998-3007.
24. Kurowska, E. M. (2002) Nitric oxide therapies in vascular diseases. Curr. Pharm. Des., 8, 155-166.
25. Stamler, J. S., Loh, E., Roddy, M. A., Currie, K. E. and Creager, M. A. (1994) Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans. Circulation, 91, 1314-1319.
26. Chan, A. W., Bhatt, D. L., Chew, D. P., Reginelli, J., Schneider, J. P., Topol, E. J. and Ellis, S. G. (2003) Relation of inflammation and benefit of statins after percutaneous coronary interventions. Circulation, 107, 1750-1756.
27. Huhle, G., Abletshauser, C., Mayer, N., Weidinger, G., Harenberg, J. and Heene, D. L. (1999) Reduction of platelet activity markers in type II hypercholesterolemic patients by a HMG-CoA reductase inhibitor. Thromb. Res., 95, 229-234.
28. Hernandez-Perera, O., Perez-Sala, D., Navarro-Antolin, J., Sanchez-Pascuala, R., Hernandez, G., Diaz, C. and Lamas, S. (1998) Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J. Clin. Invest., 101, 2711-2719.
29. McDermott, M. M., Guralnik, J. M., Greenland, P., Pearce, W. H., Criqui, M. H., Liu, K., Taylor, L., Chan, C., Sharma, L., Schneider, J. R., Ridker, P. M., Green, D. and Quann, M. (2003) Statin use and leg functioning in patients with and without lower-extremity. Circulation, 107, 757-761.
30. Mohler, E. R. 3rd, Hiatt, W. R. and Creager, M. A. (2003) Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation, 108, 1481-1486.
31. Schillinger, M., Exner, M., Mlekusch, W., Amighi, J., Sabeti, S., Muellner, M., Rumpold, H., Waqner, O. and Minar, E. (2004) Statin therapy improves cardiovascular outcome of patients with peripheral artery disease. Eur. Heart J., 25, 742-748.
32. Pepine, C. J., Handberg, E. M., Cooper-DeHoff, R. M., Marks, R. G., Kowey, P., Messerli, F. H., Mancia, G., Cangiano, J. L., Garcia-Barreto, D., Keltai, M., Erdine, S., Bristol, H. A., Kolb, H. R., Bakris, G. L., Cohen, J. D. and Parmley, W. W.; INVEST Investigators. (2003) A calcium antagonist vs a noncalcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA, 290, 2805-2816.
33. Dens, J. A., Desmet, W. J., Coussement, P., De Scheerder, I. K., Kostopoulos, K., Kerdsinchai, P., Supanantaroek, C. and Piessens, J. H. (2003) Long term effects of nisoldipine on the progression of coronary atherosclerosis and the occurrence of clinical events: the NICOLE study. Heart, 89, 887-892.
34. Stone, P. H., Muller, J. E., Turi, Z. G., Geltman, E., Jaffe, A. S. and Braunwald, E. (1983) Efficacy of nifedipine therapy in patients with refractory angina pectoris: significance of the presence of coronary vasospasm. Am. Heart J., 106, 644-652.
35. Rehnqvist, N., Hjemdahl, P., Billing, E., Bjorkander, I., Eriksson, S. V., Forslund, L., Held, C., Nasman, P. and Wallen, N, H. (1996) Effects of metoprolol vs verapamil in patients with stable angina pectoris. Eur. Heart J., 17, 76-81.